U.S. Markets close in 2 hrs 32 mins
  • S&P 500

    4,436.10
    -37.65 (-0.84%)
     
  • Dow 30

    34,565.98
    -185.34 (-0.53%)
     
  • Nasdaq

    15,036.02
    -145.91 (-0.96%)
     
  • Russell 2000

    2,233.70
    +0.79 (+0.04%)
     
  • Crude Oil

    71.93
    -0.68 (-0.94%)
     
  • Gold

    1,752.60
    -4.10 (-0.23%)
     
  • Silver

    22.42
    -0.33 (-1.44%)
     
  • EUR/USD

    1.1733
    -0.0039 (-0.3285%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • Vix

    20.32
    +1.63 (+8.72%)
     
  • GBP/USD

    1.3749
    -0.0048 (-0.3465%)
     
  • USD/JPY

    109.9460
    +0.2280 (+0.2078%)
     
  • BTC-USD

    47,530.67
    -415.95 (-0.87%)
     
  • CMC Crypto 200

    1,205.74
    -19.79 (-1.62%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Novavax to Participate in National Vaccine Advisory Committee Meeting

·2 min read

GAITHERSBURG, Md., June 17, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President, Research and Development, will participate in a session during the Department of Health and Human Services' National Vaccine Advisory Committee (NVAC) meeting, taking place virtually on June 17. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Session details are as follows:




Date:

Thursday, June 17, 2021

Time:

3:15 p.m. – 4:15 p.m. Eastern Time (ET)

Title:

Experiences in the Field: COVID-19 Vaccine Authorization and Beyond

Novavax Participant:

Gregory M. Glenn, M.D., President, Research and Development

For more information or to register for the meeting, visit: https://www.hhs.gov/webforms/nvac/index.html.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:

Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com

Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com

Media
Alison Chartan | 240-720-7804
Laura Keenan | 202-709-7521
media@novavax.com

Novavax Logo (PRNewsfoto/Novavax)
Novavax Logo (PRNewsfoto/Novavax)
Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/novavax-to-participate-in-national-vaccine-advisory-committee-meeting-301314763.html

SOURCE Novavax, Inc.